Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy.

ABSTRACT

BACKGROUND: Ectopic pregnancy is a major life- and fertility-threatening women's health concern. As a result of advances in examination technology, an increasing number of ectopic pregnancies can be diagnosed early and treated with medical methods instead of surgery. The aim of this study was to summarize the clinical features and identify the predictors of success of methotrexate (MTX) treatment of ectopic pregnancy. METHODS: This was a retrospective study of 238 ectopic pregnancies treated with MTX in the Department of Gynecology of Shaanxi Provincial People's Hospital from January 2017 to December 2017. RESULTS: Patients were divided into two groups the successful treatment group (n = 166) and the failed treatment group (n = 72). The overall success rate of MTX therapy for ectopic pregnancy was 69.75%. The mean initial beta-human chorionic gonadotropin (ß-hCG) level was significantly lower in the successful treatment group than in the failed treatment group (2538.08 IU/L versus 3533.17 IU/L, P = 0.000). The treatment success rate of the group with an initial ß-hCG concentration less than 4000 IU/L was significantly higher than that of the group with an initial ß-hCG concentration greater than 4000 IU/L. However, the success rate of the group with an initial ß-hCG concentration greater than 4000 IU/L was still relatively high (54.55%). ß-hCG levels were significantly increased on the 4th day in the failed treatment group (P = 0.000). Compared to the initial ß-hCG level, the day-4 ß-hCG level increased by more than 8.21%, indicating that the treatment was effective. The diagnostic sensitivity was 88.6%, the specificity was 74.5%, and the area under the receiver operating characteristic (ROC) curve was 0.863 (95% confidence interval (CI) 0.805-0.920). CONCLUSIONS: MTX therapy as a treatment option is safe and effective for asymptomatic, hemodynamically stable patients with ectopic pregnancies who are interested in conservative treatment, regardless of the serum ß-hCG level or adnexal mass size. The change in the ß-hCG level between the initial day and the 4th day is an effective and early predictive tool for the success of MTX therapy for ectopic pregnancy.